Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14314 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Danilo De Novellis und 48 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols, Oligopeptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Isatuximab, a novel anti‐CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa‐Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real‐world efficacy and safety are poorly reported. In this Italian multicenter real‐life observational retrospective study, efficacy and safety of the Isa‐Kd regimen were evaluated in a cohort of 103 RRMM patients. Overall response rate (ORR) was 85%, with stringent (sCR) or complete response (CR) in 18% of cases and very good partial response (VGPR) in 39%. Median PFS and OS were not reached within the study period, while 1‐year PFS and OS were 72% and 77%, respectively. Hematological toxicities were observed in 42% of subjects, and cardiac toxicities occurred in 24% of cases. Moreover, we conducted a subanalysis on patients ( N = 69) treated with Isa‐Kd after one prior line of therapy, showing an ORR of 88%, with sCR + CR in 20% of subjects, VGPR in 46%, and PR in 22% of patients. In this group, median PFS and OS were not reached, while 1‐year PFS and OS were 92% and 95%, respectively. In conclusions, our study confirmed Isa‐Kd as an effective treatment option for RRMM with a manageable safety profile even in real‐life settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
- S.C. di Ematologia e C.T.M.O., Ospedale Oncologico di Riferimento Regionale "A. Businco", Cagliari, Italy.
- Division of Hematology, Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria, Italy.
- Hematology - Department of Clinical Medicine and Surgery, University Hospital "Federico II", Naples, Italy.
- Hematology, Hospital "Antonio Cardarelli", Naples, Italy.
ORCID-Profile: Valentina Giudice
Zitieren
APA
De Novellis, D., Derudas, D., Vincelli, D., Fontana, R., Della Pepa, R., Palmieri, S., Accardi, F., Rotondo, F., Morelli, E., Gigliotta, E., Roccotelli, D., Marano, L., Barone, M. L., Cetani, G., Esposito, D., Lazzaro, A., Delle Cave, G., Serio, B., Morini, D., …, & Selleri, C. (2025). Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14314
Vancouver
De Novellis D, Derudas D, Vincelli D, Fontana R, Della Pepa R, Palmieri S, et al. Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. European Journal of Haematology. 2025. doi:10.1111/ejh.14314
BibTeX
@article{DeNovellis2025,
author = {De Novellis, Danilo and Derudas, Daniele and Vincelli, Donatella and Fontana, Raffaele and Della Pepa, Roberta and Palmieri, Salvatore and Accardi, Fabrizio and Rotondo, Francesco and Morelli, Emanuela and Gigliotta, Emilia and Roccotelli, Daniela and Marano, Luana and Barone, Maria Lucia and Cetani, Giusy and Esposito, Daniela and Lazzaro, Antonio and Delle Cave, Giuseppe and Serio, Bianca and Morini, Denise and Porrazzo, Marika and Urciuoli, Eleonora and Masucci, Chiara and Fanelli, Fulvia and Rizzo, Michela and Arcamone, Manuela and Trastulli, Fabio and Rocco, Stefano and Leone, Aldo and Bianco, Rosario and Salvatore, Flavia and Idato, Aurora and Sicari, Maria and Tosi, Patrizia and Rascato, Maria Gabriella and Di Perna, Maria and Falcone, Antonietta Pia and Morello, Lucia and Carlisi, Melania and Svanera, Gino and Annunziata, Mario and Frigeri, Ferdinando and Califano, Catello and Carella, Angelo Michele and Marcacci, Gianpaolo and Pane, Fabrizio and Risitano, Antonio Maria and Giudice, Valentina and Botta, Ciro and Selleri, Carmine},
title = {Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14314}
}
EUVIMED